8-KEarnings & Results

DEXCOM INC 8-K Report, Financial Results (Jan 12, 2010)

Filed January 12, 2010For Securities:DXCM

Summary

DexCom, Inc. (DXCM) filed an 8-K on January 12, 2010, to report preliminary, unaudited financial results for the fourth quarter of 2009. The company announced that it expects to generate approximately $6.6 million in product revenue for the fourth quarter, representing a significant sequential increase of about 43% over the third quarter of 2009. This growth was driven by strong unit sales, with approximately 2,800 starter kits sold in Q4 2009, a 31% increase from the previous quarter, and a substantial 50% sequential rise in sensor revenues. These preliminary results indicate accelerating customer adoption and product demand for DexCom's continuous glucose monitoring technology. The company's President and CEO, Terry Gregg, presented these figures at the J.P. Morgan 28th Annual Healthcare Conference, highlighting the company's positive momentum. Investors should note that these are estimated figures and not yet audited, but they provide a strong indication of the company's performance heading into 2010.

Key Highlights

  • 1DexCom anticipates Q4 2009 product revenues of approximately $6.6 million.
  • 2This represents a significant sequential revenue increase of approximately 43% compared to Q3 2009.
  • 3The company sold approximately 2,800 starter kits in Q4 2009, up 31% sequentially.
  • 4Sensor revenues experienced a robust sequential increase of approximately 50% in Q4 2009.
  • 5These preliminary results were presented by CEO Terry Gregg at the J.P. Morgan 28th Annual Healthcare Conference.
  • 6The report indicates positive sales momentum and accelerating customer adoption of DexCom's products.
  • 7The information provided is furnished and not deemed 'filed' for purposes of Section 18 of the Exchange Act.

Frequently Asked Questions

The main purpose of this 8-K filing is to report preliminary, unaudited product revenue estimates for DexCom's fourth quarter of 2009 and to announce that these results would be presented at the J.P. Morgan 28th Annual Healthcare Conference.

DexCom estimated product revenues of approximately $6.6 million for Q4 2009, which is an increase of about 43% sequentially from the third quarter of 2009.

The revenue growth was driven by increased unit sales, specifically a 31% sequential increase in starter kit sales (approximately 2,800 units) and a significant 50% sequential increase in sensor revenues.

No, the financial results reported in this 8-K filing are estimated and unaudited. The filing explicitly states that the information is furnished and not deemed 'filed' for purposes of Section 18 of the Securities Exchange Act of 1934.